Global Pulmonary Arterial Hypertension (PAH) Market: Industry Analysis & Outlook (2018-2022)

This report is available at 10% Discount for Single user License, 20% Discount for Corporate User License till 30 September 2018. To avail discount please contact at +1-888-391-5441 / sales@marketreportsonline.com.

The report “Global Pulmonary Arterial Hypertension Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering The United States and Europe region along with the global market. The report profiles the key players in the market including Johnson & Johnson, Gilead Sciences, United Therapeutics and Glaxo SmithKline.

Place a direct purchase order on this Global Pulmonary Arterial Hypertension (PAH) Market report at USD 1200 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=771054.

Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension (PH) condition, which means high blood pressure in the lungs. Many diseases such as obstructive sleep apnea (OSA), lung diseases, diastolic heart failure and diseases of the left heart can cause the pressures in the pulmonary arteries to elevate but is not pulmonary arterial hypertension.

PAH is a life threatening disease characterized by an increase in pulmonary vascular resistance that eventually leads to death. It is a rare disease, affects about 15-70 people per million in the U.S. The symptoms of PAH are difficult to diagnose as the symptoms are common to other diseases.

Pulmonary arterial hypertension is a severe condition and there is no cure to PAH at present time. Many treatments are available to improve symptoms, quality of life and to keep the condition under control. There are currently four classes of drugs approved for the treatment of PAH and 13 approved products are available for PAH in the market across these four drug classes.

Complete report on Global Pulmonary Arterial Hypertension (PAH) Market spread across 95 pages providing 4 company profiles, 6 tables and 53 figures available at http://www.marketreportsonline.com/771054.html.

The United States is the main contributor to the PAH market with the development of new therapies and increasing cases of pulmonary arterial hypertension. The U.S. has great potential in the years ahead with rising awareness about treatment options of PAH.

The global PAH market is expected to grow in the future due to increasing ageing population, rise in healthcare expenditure, growing women population, increase in obese population and high unmet needs. Key trends of this market include increasing number of cardiovascular diseases, rising government support, and consumption of junk food. However, there are some factors which can hinder the growth of the market which includes patent expiration, high cost and lack of awareness.

Browse all latest pharmaceuticals market research reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:
Market Reports Online is a comprehensive online library of more than 100,000 reports, in-depth market research studies on thousands of micro markets and a range of industries. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe. We offer online and offline support services to ensure your research requirements are met on time.

Contact Us:
Hrishikesh Patwardhan
2nd Floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune - 411001.
Maharashtra, India.
Tel: + 1 888 391 5441
E-mail: sales@marketreportsonline.com

This release was published on openPR.